ÂÜÀòÂÒÂ×

Xiaoyu Tian has a wealth of experience in the pharmaceutical industry. Xiaoyu began their career in 1990 as the Co-founder, Director of Science and Technologies at Beilu Pharmaceutical, Inc, where they initiated, drove, and completed the R&D of several medical imaging diagnostics, contributing significantly to the start-up's commercial success. In 2004, they took on the role of Research Fellow at Northeastern University, where they developed and applied NMR methods in drug discovery and investigated fundamental questions in pharmaceutical sciences. From 2011-2014, they were a Senior Research Investigator at Bristol-Myers Squibb, where they applied solution and solid-state NMR applications in pharmaceutical R&D, designed and executed molecular biophysics studies for drug candidate optimization, and developed instrumentation, experiment automation, and distributed data management strategies. Most recently, they have served as Director of Strategic Alliances at HitGen Ltd since 2014, working across the drug discovery continuum to integrate the efforts between HitGen innovation units while interfacing and providing HitGen technologies to clients in the development of their medicines. Xiaoyu has also collaborated with pharmaceutical scientists from industry and academia to foster drug discovery partnerships with HitGen DNA Encoded Library technologies and discoveries, as well as providing scientific expertise to internal functional units on structure design, drugbility, and advanced analytical method development for effective compound QC and hit-to-lead studies.

Xiaoyu Tian holds a Ph.D. in Pharmaceutical Science from the University of Connecticut. Prior to that, they earned a Master of Science (M.Sc.) in Quantum Electronics (NMR Spectroscopy and Imaging) from Peking University, and a Bachelor of Science (BS) in Electrical and Electronics Engineering from the same institution.